Company news

Oncolytics Biotech Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers

October 27, 2026

Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer

October 20, 2026

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment

October 14, 2026

Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update

October 12, 2026

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy

September 29, 2026

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study

September 28, 2026

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer

September 10, 2026

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

August 18, 2026

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

July 20, 2026

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

July 13, 2026

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

June 16, 2026

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

June 1, 2026

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

May 31, 2026

From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story

May 25, 2026

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

May 22, 2026

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

May 4, 2026

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

April 26, 2026

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

April 6, 2026

Oncolytics Biotech Completes Domicile Change to the United States

April 2, 2026

Oncolytics Biotech® Completes Domicile Change to the United States

April 1, 2026

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

March 19, 2026

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

March 2, 2026

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

February 24, 2026

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

February 4, 2026

Oncolytics Biotech Announces Results of Special Meeting of Shareholders

January 16, 2026

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

January 15, 2026

Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

January 14, 2026

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

January 12, 2026

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

January 9, 2026

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

January 8, 2026

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris

January 6, 2026

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

December 15, 2025

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

December 8, 2025

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

November 19, 2025

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

November 18, 2025

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

November 3, 2025

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

October 28, 2025

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

October 19, 2025

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

September 28, 2025

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

September 15, 2025

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

September 7, 2025

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

September 1, 2025

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

August 28, 2025

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

August 26, 2025

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

August 14, 2025

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

August 14, 2025

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

August 11, 2025

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

August 8, 2025

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

August 8, 2025

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

August 5, 2025

Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.